Cannabinoid Composition for Migraine Biomarker Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for migraine pain, frequency, and fibromyalgia pain are often ineffective for those diagnosed with these disorders, including triptan drugs, ergotamines, NSAIDs, opioids, and other therapies, highlighting a need for an effective treatment that modulates biomarkers of central and peripheral sensitization to reduce pain and associated symptoms.

Innovation Solution

Administering a pharmaceutically effective amount of minor cannabinoids alone or in combination with THC and CBD to modulate biomarkers such as NMDA, glutamate, CGRP, and others, thereby reducing migraine pain, frequency, and fibromyalgia pain, and alleviating symptoms like photophobia and nausea.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments (triptans, ergotamines, NSAIDs, opioids) are administered, then migraine pain and fibromyalgia pain are targeted, but treatment effectiveness is insufficient for many patients

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidresponse variability among patients

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the chemical parameter by introducing minor cannabinoids (CBG, CBC, CBDV) in combination with THC and CBD, creating a new compositional parameter that modulates multiple biomarkers (NMDA, glutamate, CGRP, FAAH) simultaneously, thereby improving treatment reliability across diverse patient populations

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs a composite cannabinoid formulation combining multiple cannabinoids (THC, CBD, and minor cannabinoids) in specific ratios, creating a synergistic composite material that addresses multiple pain pathways and biomarkers, enhancing overall treatment effectiveness and patient response consistency

Inventive Principle:

Principle #40Composite materials

2Reliability

If THC is administered to reduce migraine pain, then analgesic effect is achieved, but undesired side effects increase

Engineering Contradiction:

Improvepain relief effectivenessVSAvoidTHC side effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful side effects of THC into benefits by combining it with CBD and minor cannabinoids, where CBD and minor cannabinoids modulate the psychoactive effects and side effects of THC while preserving its analgesic properties, thereby transforming a harmful profile into a beneficial therapeutic profile

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent introduces CBD and minor cannabinoids as intermediary substances that mediate between THC and the patient's system, reducing THC's harmful side effects (psychoactivity, anxiety) while maintaining its pain-relieving effects, thus acting as protective intermediaries

Inventive Principle:

Principle #24Intermediary (Mediator)

3Ease of operation

If single cannabinoid treatments are administered, then simplified dosing is achieved, but biomarker modulation effectiveness is reduced

Engineering Contradiction:

Improvedosing simplicityVSAvoidbiomarker modulation efficacy

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent creates a universal multi-functional cannabinoid composition where minor cannabinoids (CBG, CBC, CBDV) perform multiple functions: they modulate multiple biomarkers (NMDA, glutamate, CGRP, FAAH), enhance THC's analgesic effects, reduce side effects, and provide broad-spectrum coverage for different pain mechanisms, thereby maintaining dosing simplicity while achieving comprehensive biomarker modulation

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20260069616A1Compositions comprising cannabinoids and methods of use

Publication Date: 2026.03.12 SCHEDULE 1 THERAPEUTICS INC

AI summary

The present disclosure is related to the use of compositions and their use in reducing and treating pain.